BioSpace
The approval of Ionis Pharmaceuticals’ Tryngolza for severe hypertriglyceridemia could spur “substantial growth” for the product, according to William Blair.
BioSpace
The approval of Ionis Pharmaceuticals' Tryngolza for severe hypertriglyceridemia could spur "substantial growth" for the product, according to William Blair.
BioSpace
The approval of Ionis Pharmaceuticals’ Tryngolza for severe hypertriglyceridemia could spur “substantial growth” for the product, according to William Blair.